KOSDAQBiotech & Pharma074430

Aminologics

₩947▼ 0.63%2026-11-18 close
Market Cap
₩84.6B
Turnover
₩37,156,121
Volume
40K
Shares out.
89.3M
PER
55.6×
PBR
1.4×
EPS
₩17
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales recovery, with largest-shareholder dependence at issue

Sales and operating profit have grown since the return to profit in 2025, but most revenue comes from dealings with the largest shareholder, which is the starting point for reading this stock.

  1. 1

    Sales reached KRW 22 billion in 2025, up 31.1% from the prior year, and operating profit of KRW 3.59 billion turned the 2024 operating loss into a profit.

  2. 2

    Third-quarter 2026 sales were KRW 7.41 billion, up 23.5% year on year, and operating profit was KRW 1.87 billion, up 33.4%, but the company posted a net loss attributable to controlling shareholders of KRW 270 million.

  3. 3

    Most third-quarter 2026 sales, KRW 6.51 billion on a consolidated basis or 87.8% of the total, came from transactions with the largest shareholder group.

  4. 4

    The combined stake of the largest shareholder and related parties rose to 41.79% as of September 10, 2026, following the exercise of a call option on a convertible bond.

  5. 5

    The stock was designated a Caution Stock on January 7, 2026 and released on January 23, with a one-day Attention Stock classification afterward, so it has a market-alert history.

02

Business structure

Aminologics runs two businesses: amino acid derivative compounds and active pharmaceutical ingredients (APIs) supplied to domestic pharmaceutical manufacturers. In the third quarter of 2026, the amino acid segment generated KRW 6.78 billion of KRW 7.41 billion in sales, or 91.5%.

The 2023 mix was roughly 70% amino acids and 30% APIs. The amino acid lineup includes protected amino acids, amino esters and oligopeptides, which the company has commercialized to broaden its portfolio.

APIs go into medicines for stroke, eye diseases and dermatitis, as well as cosmetic ingredients, and are supplied to domestic drug makers. The company focuses on non-natural amino acids and chiral technology, areas where few producers worldwide have production capacity.

Customer concentration is high: third-quarter 2026 sales to the largest shareholder group were KRW 6.51 billion on a consolidated basis, or 87.8% of the total, and the same group is also a counterparty for raw material purchases and contract manufacturing. The company has two subsidiaries, both unlisted.

Its model differs from large contract manufacturers and biosimilar-focused peers, which limits direct comparison.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6B₩1.4B23.4%
2025Q4₩6.5B₩1.5B22.4%
2026Q1₩5.4B₩600M11.7%
2026Q2₩8.2B₩2B24.1%
2026Q3₩7.4B₩1.9B25.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.3B₩7B-₩7.3B25.7%−14.2%8.1%
2023₩20.9B₩1.5B₩2.4B7.0%4.5%6.0%
2024₩16.8B-₩2.2B-₩1.6B−12.8%−3.1%9.9%
2025₩22B₩3.6B₩3.5B16.3%6.3%50.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales were KRW 27.3 billion in 2022, KRW 20.9 billion in 2023 (down 23.6% year on year), and KRW 16.8 billion in 2024 (down 19.6%), before rebounding to KRW 22 billion in 2025 (up 31.1%). 2022 was the largest year and 2024 the smallest within 2022 to 2025.

Operating profit fell from KRW 7.03 billion in 2022 (operating margin 25.7%) to KRW 1.46 billion in 2023 (down 79.2%, margin 7.0%), then turned into an operating loss of KRW 2.15 billion in 2024 (margin -12.8%). Operating profit of KRW 3.59 billion in 2025 (margin 16.3%) marked a return to profit.

Net income attributable to controlling shareholders moved between losses and profits: a net loss of KRW 7.28 billion in 2022, a profit of KRW 2.44 billion in 2023, a net loss of KRW 1.62 billion in 2024 and a profit of KRW 3.52 billion in 2025.

Net income including non-controlling interests was also KRW 3.52 billion in 2025.

Quarterly, third-quarter 2025 sales of KRW 6.01 billion and operating profit of KRW 1.4 billion were followed by fourth-quarter sales of KRW 6.52 billion (up 8.6% from the prior quarter) and operating profit of KRW 1.46 billion, yet the fourth quarter posted a net loss attributable to controlling shareholders of KRW 258 million.

First-quarter 2026 sales of KRW 5.38 billion (down 17.5%) and operating profit of KRW 630 million (down 57.0%) were followed by second-quarter sales of KRW 8.25 billion (up 53.2%) and operating profit of KRW 1.98 billion (up 215.0%).

Third-quarter 2026 sales of KRW 7.41 billion and operating profit of KRW 1.87 billion came with a net loss attributable to controlling shareholders of KRW 270 million, so operating and net results diverged again. Net income attributable to controlling shareholders over the last four quarters totaled KRW 1.53 billion.

The debt ratio rose from 9.9% in 2024 to 50.3% in 2025, with total liabilities of KRW 28.2 billion and total equity of KRW 56 billion at year-end 2025. The KRW 20 billion convertible bond approved in June 2025 appears to be a factor in the higher liabilities.

Operating cash flow was KRW 5.23 billion in 2022, -KRW 218 million in 2023, KRW 7.47 billion in 2024 and KRW 2.54 billion in 2025.

05

Industry analysis

The core areas for Aminologics are non-natural amino acids and chiral technology. Few producers worldwide have production capacity in these areas, which are generally regarded as high value-added.

Amino acids are used in medicines, food, feed, cosmetics and agricultural chemicals, and the company focuses on pharmaceutical ingredients and amino acid derivatives within that range.

Downstream demand comes from orders by domestic drug makers, with stroke, eye disease and dermatitis treatments and cosmetic ingredients as the main uses. The prescription and production plans of those downstream products can therefore affect sales indirectly.

In terms of cycle position, sales fell in 2023 and again in 2024 from KRW 27.3 billion in 2022 before rebounding in 2025, and quarterly sales in 2026 ranged from KRW 5.38 billion to KRW 8.25 billion, so quarter-to-quarter variation is large.

Among listed peers in biopharma, large companies such as Samsung Biologics and Celltrion focus on large-scale production and biopharmaceuticals, so their business models differ.

A direct listed competitor in amino acid derivatives is therefore hard to identify, and the scarcity of non-natural amino acid technology is the main point of differentiation. Market share comparisons with numbers are limited.

06

Outlook

The company has not disclosed a quantitative full-year guidance in the materials used here, so the outlook is limited to confirmed facts.

Quarterly sales from the first to the third quarter of 2026 were KRW 5.38 billion, KRW 8.25 billion and KRW 7.41 billion, and operating profit was KRW 630 million, KRW 1.98 billion and KRW 1.87 billion. The amino acid segment accounted for 91.5% of third-quarter 2026 sales and remains the center of growth.

On the financing side, a KRW 20 billion convertible bond was approved in June 2025. In September 2026, the largest shareholder and related parties were designated as holders of the call option on the fourth convertible bond, and after acquiring the option on September 10, their combined stake rose to 41.79%.

The filing states the purpose as influence over management, including appointing and dismissing directors and amending the articles. Voting shares outstanding rose from 87,826,844 shares to 88,140,322 shares.

At the March 31, 2026 annual general meeting, the 29th-term financial statements were approved and four internal directors were re-elected; as a venture company, the company has no obligation to appoint outside directors.

No public figures on capacity expansion or new product timing are currently available, so the next capex disclosure in the periodic report is the checkpoint. The 2026 annual report, the next periodic report, is expected around late March 2027, based on last year's submission timing.

07

Valuation

PER
55.6×
PBR
1.4×
ROE
2.6%
EPS
₩17
BPS
₩669
Dividend per share
₩0

The price-to-book ratio is above 1x, meaning the shares trade at a premium to book value.

The price-to-earnings ratio is hard to read because earnings are small, and net income attributable to controlling shareholders totaled only KRW 1.53 billion over the last four quarters, so the multiple looks high relative to the earnings base.

Equity attributable to controlling shareholders at year-end 2025 was KRW 56 billion, the same as total equity, so nearly all equity belongs to controlling shareholders.

The shift from an operating loss in 2024 to a profit in 2025 is a turnaround, but profits and losses alternated from 2022, so the multi-year trend is still short. The dividend yield is below the industry average.

In January 2026, the exchange designated the stock a Caution Stock based on a more than 60% rise over five trading days, a sign of large price swings. Reading valuation alongside this alert history and the largest shareholder's stake gives the most accurate factual picture.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Recovery in operating profitability

The operating margin recovered to 16.3% in 2025 from -12.8% in 2024. Operating profit was KRW 1.98 billion in the second quarter of 2026 and KRW 1.87 billion in the third quarter, with third-quarter operating profit up 33.4% year on year. Whether this level holds will be shown by the operating margin in the next periodic report.

Scarcity of non-natural amino acid technology

Non-natural amino acids and chiral technology are described as areas where few producers worldwide have production capacity. The company has commercialized protected amino acids, amino esters and oligopeptides as application products.

Amino acid segment sales were KRW 6.78 billion in the third quarter of 2026, or 91.5% of the total. Whether this technology scarcity turns into sales growth will show up in the amino acid segment trend.

Financial capacity and profit run

Total equity was KRW 56 billion and total liabilities were KRW 28.2 billion at year-end 2025. Operating cash flow was KRW 2.54 billion in 2025, a positive figure.

After the 2025 return to profit, net income attributable to controlling shareholders was KRW 1.07 billion in the first quarter of 2026 and KRW 990 million in the second quarter.

09

Bear factors

Sales concentrated in related parties

Sales to the largest shareholder group were KRW 6.51 billion on a consolidated basis in the third quarter of 2026, or 87.8% of the total. The same group is both a customer and a counterparty for raw material supply and contract manufacturing, so the trade flows in both directions. Pricing and terms are the points to check in the related-party transaction disclosures of the periodic reports.

Operating profit and net income diverging

In the fourth quarter of 2025 and the third quarter of 2026, operating profit was KRW 1.46 billion and KRW 1.87 billion respectively, yet both quarters recorded a net loss attributable to controlling shareholders. The third-quarter 2026 loss was KRW 270 million.

The drivers, such as non-operating items or taxes, can be traced in the income statement of the relevant quarterly report, and whether operating gains carry through to net income remains unclear.

Share price volatility and ownership structure

The stock was designated a Caution Stock on January 7, 2026 and released on January 23, then classified as an Attention Stock for one day. The exchange also set out conditions for re-designation.

With the combined stake of the largest shareholder and related parties rising to 41.79%, the share of shares available to trade on the market has fallen accordingly.

10

Risk factors

Dependence on related-party trade

Because most sales come from dealings with the largest shareholder, changes in orders from that counterparty can move results directly. A share of 87.8% in the third quarter of 2026 means customer diversification remains at an early stage.

Whether diversification progresses will show in the sales breakdown of the next periodic report. Press coverage also pointed to direct export expansion as a factor to watch.

Market alerts and share price volatility

The January 2026 Caution Stock designation followed a rise of more than 60% over five trading days. Under the caution stage, the exchange stated that trading restrictions apply, including a 100% margin deposit and no margin purchases. The exchange also said further sharp gains could lead to re-designation as a higher-risk stock.

Dilution and concentration of decision-making

Exercise of the convertible bond call option raised voting shares outstanding from 87,826,844 to 88,140,322. The largest shareholder group's stake rose to 41.79%, and the filing states the purpose as influence over management. For minority holders, dilution and concentrated decision-making occur together. The absence of an outside director requirement is another point to note on oversight.

11

What to watch next

  1. Early February 2027 (based on last year's timing)

    The fourth-quarter and full-year 2026 preliminary results are expected in a disclosure of a change in profit structure, as in the prior year, when the filing came out on February 6, 2026. Watch the annual sales trend and the direction of fourth-quarter operating profit and net income attributable to controlling shareholders.

  2. Around late March 2027

    The 2026 annual report and the annual general meeting are due. Last year the annual report was filed on March 23, 2026 and the meeting was held on March 31. The annual operating margin, the related-party sales share and changes in convertible-bond-related liabilities are the points to confirm.

  3. Around mid-May 2027

    The first-quarter 2027 quarterly report is expected. Last year's first-quarter report was filed on May 15, 2026. Whether sales move from the KRW 5.38 billion of the first quarter of 2026, and whether net income attributable to controlling shareholders stays positive, are the points to check.

12

Overall view

Aminologics is a bio-materials company that handles amino acid derivatives and pharmaceutical ingredients together, and its full-year 2025 results turned to a profit. Operating profit rose in the second and third quarters of 2026, showing a recovery in profitability.

However, most sales come from dealings with the largest shareholder and related parties, and in the third quarter of 2026 a net loss attributable to controlling shareholders occurred despite higher operating profit. The rise in the largest shareholder group's stake also gives it greater influence over management.

The strengths are the recovery in operating margin, the scarcity of non-natural amino acid technology and a stable capital structure, while the weaknesses are trade concentration, volatile net income and the market-alert history.

Both sets of factors deserve equal weight, and which side prevails will show in the numbers of the next periodic reports. The next checkpoints are the preliminary full-year 2026 results, the 2026 annual report and the first-quarter 2027 quarterly report. This report offers no investment opinion and provides information based only on disclosures and facts.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. medicopharma.co.kr
  2. comp.fnguide.com
  3. comp.wisereport.co.kr
  4. butler.works
  5. goinsider.kr
  6. m.thinkpool.com
  7. stock.finup.co.kr
  8. news.nate.com
  9. m.thinkpool.com
  10. news.nate.com
  11. m.news.nate.com
  12. topstarnews.net
  13. topstarnews.net
  14. topstarnews.net
  15. medicopharma.co.kr
  16. datatooza.com
  17. m.thinkpool.com
  18. tipranks.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis